Sandoz Group AG Registered Shares
SDZ: XSWX (CHE)
| Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
|---|---|---|---|
| CHF 39.00 | Rtdh | Tvznjnfdz |
Sandoz Earnings: Generics Flat, but Results Look Good on Lofty Biosimilars From Hyrimoz, Omnitrope
/s3.amazonaws.com/arc-authors/morningstar/b76d1412-e5af-4b94-8222-8cb66fe23dbe.jpg)
No-moat Sandoz reported first-quarter earnings that came largely as we expected. Total sales of $2.5 billion were up 4.5%, or 6% in constant currencies, as growth across all three regions and a strong biosimilars business made for a solid start to the year. After adjusting our model and baking in a more favorable USD/CHF exchange rate compared with last quarter, we slightly raised our fair value estimate to CHF 32 per share from CHF 31.